JP2022512584A - 角皮症を処置するためのｅｇｆｒインヒビター - Google Patents

角皮症を処置するためのｅｇｆｒインヒビター Download PDF

Info

Publication number
JP2022512584A
JP2022512584A JP2021518152A JP2021518152A JP2022512584A JP 2022512584 A JP2022512584 A JP 2022512584A JP 2021518152 A JP2021518152 A JP 2021518152A JP 2021518152 A JP2021518152 A JP 2021518152A JP 2022512584 A JP2022512584 A JP 2022512584A
Authority
JP
Japan
Prior art keywords
palmoplantar
egfr
syndrome
patient
keratosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021518152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512584A5 (enExample
Inventor
ボーデメール，クリスティーヌ
グレコ，セリーヌ
ブーシェイ，クロード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Fondation Imagine
Universite Paris Cite
Universite Paris Saclay
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Universite de Paris
Fondation Imagine
Universite Paris Saclay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Universite de Paris, Fondation Imagine, Universite Paris Saclay filed Critical Assistance Publique Hopitaux de Paris APHP
Publication of JP2022512584A publication Critical patent/JP2022512584A/ja
Publication of JP2022512584A5 publication Critical patent/JP2022512584A5/ja
Priority to JP2024174514A priority Critical patent/JP2025004113A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2021518152A 2018-10-04 2019-10-03 角皮症を処置するためのｅｇｆｒインヒビター Pending JP2022512584A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024174514A JP2025004113A (ja) 2018-10-04 2024-10-03 角皮症を処置するためのｅｇｆｒインヒビター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306306.4 2018-10-04
EP18306306 2018-10-04
PCT/EP2019/076803 WO2020070239A1 (en) 2018-10-04 2019-10-03 Egfr inhibitors for treating keratodermas

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024174514A Division JP2025004113A (ja) 2018-10-04 2024-10-03 角皮症を処置するためのｅｇｆｒインヒビター

Publications (2)

Publication Number Publication Date
JP2022512584A true JP2022512584A (ja) 2022-02-07
JP2022512584A5 JP2022512584A5 (enExample) 2022-10-11

Family

ID=63857839

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021518152A Pending JP2022512584A (ja) 2018-10-04 2019-10-03 角皮症を処置するためのｅｇｆｒインヒビター
JP2024174514A Pending JP2025004113A (ja) 2018-10-04 2024-10-03 角皮症を処置するためのｅｇｆｒインヒビター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024174514A Pending JP2025004113A (ja) 2018-10-04 2024-10-03 角皮症を処置するためのｅｇｆｒインヒビター

Country Status (9)

Country Link
US (1) US12491186B2 (enExample)
EP (1) EP3860608A1 (enExample)
JP (2) JP2022512584A (enExample)
CN (1) CN113194954A (enExample)
AU (1) AU2019352741A1 (enExample)
BR (1) BR112021006407A8 (enExample)
CA (1) CA3115038A1 (enExample)
IL (1) IL282041A (enExample)
WO (1) WO2020070239A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4003299A4 (en) * 2019-07-24 2023-08-23 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical tapinarof-egfr inhibitor compositions
WO2021090322A1 (en) * 2019-11-06 2021-05-14 Sol-Gel Technologies Ltd. Method of treating palmoplantar keratoderma
WO2021204843A1 (en) 2020-04-07 2021-10-14 Laboratoires C.T.R.S. Topical use of erlotinib for treating keratodermas in children
KR102536315B1 (ko) * 2020-09-11 2023-05-25 아주대학교산학협력단 네라티닙을 유효성분으로 포함하는 퇴행성 관절염 예방 또는 치료용 조성물
CN120309699B (zh) * 2025-04-18 2025-11-21 中国医学科学院基础医学研究所 稀释诱导相分离多肽及其应用

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
CA2102780C (en) 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
CN1038583C (zh) 1993-08-09 1998-06-03 钟纺株式会社 酰基苯基甘氨酸衍生物及以其为有效成分的胶原酶活性亢进所致疾病的防治药物
FI960803L (fi) 1993-08-23 1996-04-22 Immunex Corp TNF-alfa-sekreetion inhibiittoreita
JPH08503971A (ja) 1993-10-01 1996-04-30 チバ−ガイギー アクチェンゲゼルシャフト ピリミジンアミン誘導体及びその調製のための方法
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
DE59500788D1 (de) 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
JP4249804B2 (ja) 1995-04-03 2009-04-08 ノバルティス・アクチエンゲゼルシャフト ピラゾール誘導体およびその製造法
JP3814696B2 (ja) 1995-04-17 2006-08-30 住友精化株式会社 芳香族またはヘテロ芳香族スルホニルハライド類の製造方法
US5691381A (en) 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
DE69632821T2 (de) 1995-04-25 2005-08-25 Daiichi Fine Chemical Co., Ltd., Takaoka In wasser hochlöslicher metalloproteinase-inhibitor
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5650415A (en) 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
GB9513331D0 (en) 1995-06-30 1995-09-06 British Biotech Pharm Matrix metalloproteinase inhibitors
EP0836605B1 (en) 1995-07-06 2002-02-06 Novartis AG Pyrrolopyrimidines and processes for the preparation thereof
DK9500262U4 (da) 1995-07-07 1996-10-07 Bonus Energy As Bundramme til vindmøllehus samt vindmølle omfattende samme
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
SK63498A3 (en) 1995-11-14 1999-01-11 Du Pont Merck Pharma Novel macrocyclic compounds as metalloprotease inhibitors
US6281352B1 (en) 1995-11-14 2001-08-28 Dupont Pharmaceuticals Company Macrocyclic compounds as metalloprotease inhibitors
US5665777A (en) 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
GB9523637D0 (en) 1995-11-18 1996-01-17 British Biotech Pharm Synthesis of carboxylic acid derivatives
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
JP2000500761A (ja) 1995-11-23 2000-01-25 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
DE69633947T2 (de) 1995-12-08 2005-12-01 Agouron Pharmaceuticals, Inc., San Diego Zwischenprodukte zur Herstellung von Metallproteinasehemmern
WO1997024117A1 (en) 1996-01-02 1997-07-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
AU1441497A (en) 1996-01-23 1997-08-20 Novartis Ag Pyrrolopyrimidines and processes for their preparation
JP3406763B2 (ja) 1996-01-30 2003-05-12 東レ・ダウコーニング・シリコーン株式会社 シリコーンゴム組成物
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19608588A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19629652A1 (de) 1996-03-06 1998-01-29 Thomae Gmbh Dr K 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6051577A (en) 1996-03-15 2000-04-18 Novartis Ag N-7-heterocyclyl pyrrolo[2,3-D]pyrimidines and the use thereof
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
WO1997042168A1 (en) 1996-05-06 1997-11-13 Zeneca Limited Thio derivatives of hydroxamic acids
GB9609795D0 (en) 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds
GB9609794D0 (en) 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds
EP0907642B1 (en) 1996-06-24 2005-11-02 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
GB9613547D0 (en) 1996-06-27 1996-08-28 Pharmacia Spa Matrix metalloproteinase inhibitors
DE69716916T2 (de) 1996-07-13 2003-07-03 Glaxo Group Ltd., Greenford Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EA199900021A1 (ru) 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
GB9715962D0 (en) 1996-08-23 1997-10-01 Zeneca Ltd Sulfonamides
AU720429B2 (en) 1996-08-23 2000-06-01 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
AU4779897A (en) 1996-10-02 1998-04-24 Novartis Ag Fused pyrazole derivatives and processes for their preparation
ES2239779T3 (es) 1996-10-02 2005-10-01 Novartis Ag Derivados de pirimidina y procedimientos para la preparacion de los mismos.
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
AU743901B2 (en) 1996-10-16 2002-02-07 Wyeth Holdings Corporation Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors
CN1105101C (zh) 1996-10-16 2003-04-09 美国氰胺公司 作为基质金属蛋白质酶和TACE抑制剂的β－亚磺酰氨基异羟肟酸
AU743898B2 (en) 1996-10-16 2002-02-07 American Cyanamid Company The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
HUP0000641A3 (en) 1996-10-16 2001-02-28 American Cyanamid Company Madi Ortho-sulfonamido aryl hydroxamic acid derivatives, their use, as matrix metalloproteinase and tace inhibitors and pharmaceutical compositions containing them
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
ZA9818B (en) 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
ZA9820B (en) 1997-01-07 1998-07-02 Abbott Lab Macrocyclic inhibitors of matrix metalloproteinases and tnf x secretion
IL130802A0 (en) 1997-01-23 2001-01-28 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
KR20000070751A (ko) 1997-02-05 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
KR20000075681A (ko) 1997-02-26 2000-12-26 그레이엄 브레레톤, 레슬리 에드워즈 메탈로프로테아제 억제제로서의 후위 히드록사메이트 유도체
GEP20022626B (en) 1997-02-27 2002-02-25 American Cyanamid Company Us N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl Sulfanyl, Sulfinil or Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix Metalloproteinase Inhibitors
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
CA2285372A1 (en) 1997-04-01 1998-10-08 Melwyn A. Abreo Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
AU8858398A (en) 1997-07-10 1999-02-08 Pharmacia & Upjohn S.P.A. Matrix metalloproteinase inhibitors
IT1296305B1 (it) 1997-07-17 1999-06-25 Polifarma Spa Inibitori di metalloproteinasi loro uso terapeutico e procedimento per la produzione del composto di partenza nella loro
WO1999006410A1 (en) 1997-08-04 1999-02-11 Amgen Inc. Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
WO1999007701A1 (en) 1997-08-05 1999-02-18 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
DE59703834D1 (de) 1997-08-25 2001-07-19 Hydac Filtertechnik Gmbh Filterelement mit kunststoff-filtermantel
DK1021413T3 (da) 1997-10-06 2003-10-06 Wyeth Corp Fremstilling og anvendelse af ortho-sulfonamido-bicykliske heteroarylhydroxamsyrer som matrixmetalloproteinase- og TACE-inhibitorer
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
EP1038864A1 (en) 1997-12-12 2000-09-27 Fuji Yakuhin Kogyo Kabushiki Kaisha Novel metalloproteinase inhibitors
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
BR9907746A (pt) 1998-01-27 2000-10-17 American Cyanamid Co ácidos 2,3,4,5-tetraidro-1h[1,4]-benzodiazepina-3-hidroxâmic os como inibidores de matriz de metaloproteinase
ID25639A (id) 1998-02-19 2000-10-19 American Cyanamid Co Alkil, aril atau heteroarilamida tersubstitusi n-hidroksi-2-(alkil, aril, atau heteroaril sulfanil, sulfinil atau sulfonil)-3 sebagai inhibitor matriks mataloproteinase
CN1301265A (zh) 1998-05-14 2001-06-27 杜邦药品公司 新的用作金属蛋白酶抑制剂的取代的芳基异羟肟酸
CA2332946A1 (en) 1998-05-22 1999-12-02 Welfide Corporation Hydroxamic acid derivative and pharmaceutical use thereof
US6552223B1 (en) 1998-08-31 2003-04-22 Astrazeneca Ab N-hydroxacylamino compounds, process for their preparation and pharmaceutical compositions containing them
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
JP3913983B2 (ja) 1998-12-11 2007-05-09 エフ．ホフマン−ラ ロシュ アーゲー ＴＮＦ−α阻害剤としての環式ヒドラジン誘導体
PT1144369E (pt) 1999-01-27 2004-11-30 Wyeth Corp Acidos hidroxamicos de arilsulfonamidas acetilenicas e de amidas de acido fosfinico acetilenicas inibidores de tace
AR035478A1 (es) 1999-01-27 2004-06-02 Wyeth Corp Acido amida-hidroxamico, acido acetilenico, beta-sulfonamido y fosfinico como inhibidores de la tace, uso de los mismos para la manufactura de un medicamento y composicion farmaceutica que los contiene
AR022423A1 (es) 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
CN1224612C (zh) 1999-01-27 2005-10-26 惠氏控股有限公司 炔基磺酰胺硫醇tace抑制剂
AR035313A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
AR022422A1 (es) 1999-01-27 2002-09-04 American Cyanamid Co Inhibidores de tace acetilenicos de acido hidroxamico de heteroarilfulfonamida y amida del acido fosfinico
AR022424A1 (es) 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos ortosulfonamido acetilenico e hidroxamico biciclico heteroarilo amido de acido fosfinico como inhibidores tace, composicionfarmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
AR035311A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
AU2320500A (en) 1999-02-02 2000-08-25 Shionogi & Co., Ltd. Sulfonamide derivatives having cyclic structures
AP2001002240A0 (en) 1999-02-08 2001-09-30 Searle & Co Sufamato hydroxamic acid metalloprotease inhibitor.
CA2367963A1 (en) 1999-03-22 2000-09-28 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
WO2000059285A2 (en) 1999-04-02 2000-10-12 Du Pont Pharmaceuticals Company NOVEL LACTAM INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE
GB9911073D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
EP1177173A1 (en) 1999-05-12 2002-02-06 G.D. Searle & Co. Hydroxamic acid derivatives as matrix metalloprotease inhibitors
GB9911071D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
GB9911075D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd HYdroxamic and carboxylic acid derivatives
AU4614000A (en) 1999-05-17 2000-12-05 Daiichi Fine Chemical Co., Ltd. Novel hydroxamic acid derivatives
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
KR20020005769A (ko) 1999-06-04 2002-01-17 다비드 에 질레스 메탈로프로테이나제의 억제제
TR200202164T2 (tr) 1999-08-18 2002-11-21 Warner-Lambert Company Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri.
GB9922825D0 (en) 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
US6632667B1 (en) 1999-10-28 2003-10-14 Isis Pharmaceuticals, Inc. Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE)
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB9929979D0 (en) 1999-12-17 2000-02-09 Darwin Discovery Ltd Hydroxamic acid derivatives
EP1252143A1 (en) 2000-01-27 2002-10-30 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
US6989139B2 (en) 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
JP2003524008A (ja) 2000-02-21 2003-08-12 アストラゼネカ・アクチエボラーグ アリールピペラジンおよびアリールピペリジン、およびそれらのメタロプロテイナーゼ阻害剤としての使用
AU2001232113A1 (en) 2000-02-21 2001-09-03 Astrazeneca Ab Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
MXPA02008111A (es) 2000-02-21 2002-11-29 Astrazeneca Ab N-hidroxiformamidas substituidas con piperidina y piperazina como inhibidores de metaloproteinasas.
AR027943A1 (es) 2000-02-25 2003-04-16 Wyeth Corp Acidos orto-sulfonamido aril hidroxamicos como inhibidores de metaloproteinasa de matriz y preparacion de los mismos
CN1481377A (zh) 2000-03-17 2004-03-10 ����˹�ж�-����˹˹����ҩƷ��˾ 作为基质金属蛋白酶和TNF-α的抑制剂的环β-氨基酸衍生物
AU2001250850A1 (en) 2000-03-17 2001-10-03 Dupont Pharmaceuticals Company Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
EP1286994A1 (en) 2000-05-15 2003-03-05 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
WO2001087870A1 (en) 2000-05-15 2001-11-22 Darwin Discovery Limited Hydroxamic acid derivatives
US6620823B2 (en) 2000-07-11 2003-09-16 Bristol-Myers Squibb Pharme Company Lactam metalloprotease inhibitors
GB0017435D0 (en) 2000-07-14 2000-08-30 Pharmacia & Upjohn Spa 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivatives
US20060084691A1 (en) * 2004-10-18 2006-04-20 Bilal Piperdi Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
WO2009091889A1 (en) 2008-01-18 2009-07-23 Georgetown University Treatment of skin disorders with egfr inhibitors
KR101822444B1 (ko) 2010-07-08 2018-01-26 가켄 세이야쿠 가부시키가이샤 N-히드록시포름아미드 유도체 및 그를 함유하는 의약

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. AM. ACAD. DERMATOL., vol. 63, [2], JPN6023033686, 2010, pages 58 - 59, ISSN: 0005494201 *
J. INVEST. DERMATOL., vol. 135, [11], JPN6023033687, 2015, pages 2879 - 2883, ISSN: 0005494202 *
JAMA DERMATOL., vol. 150, [3], JPN6023033688, 2014, pages 303 - 306, ISSN: 0005494203 *
皮膚疾患分野 掌蹠角化症(平成24年度), 難病情報センター, [ONLINE], INTERNET ARCHIVE:WAYBACK MACHINE，2, JPN6024021435, ISSN: 0005494204 *

Also Published As

Publication number Publication date
BR112021006407A8 (pt) 2022-12-06
WO2020070239A1 (en) 2020-04-09
EP3860608A1 (en) 2021-08-11
US12491186B2 (en) 2025-12-09
BR112021006407A2 (pt) 2021-07-27
US20210393632A1 (en) 2021-12-23
IL282041A (en) 2021-05-31
AU2019352741A1 (en) 2021-05-06
CA3115038A1 (en) 2020-04-09
JP2025004113A (ja) 2025-01-14
CN113194954A (zh) 2021-07-30

Similar Documents

Publication Publication Date Title
US12491186B2 (en) EGFR inhibitors for treating keratodermas
JP6473103B2 (ja) 癌の化学療法および放射線療法の際に細胞を保護するための局所的血管収縮剤および方法
CN110917124B (zh) 软性抗胆碱能药类似物的制剂
JPH05178764A (ja) 局所用あるいは経皮用製品におけるジブチルアジペートとイソプロピルミリステートの用途
JPH11502513A (ja) 糖尿病性ニューロパシーの処置方法
US20030181515A1 (en) Methods of using kavalactone compositions
WO2014130638A1 (en) Combinations of indigo naturalis and berberine and uses thereof
AU2022223701A1 (en) Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
CA3087124A1 (en) Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof
WO2017129108A1 (zh) 一种用于治疗皮肤病的硅凝胶
US10201535B2 (en) Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
CN104519861A (zh) 治疗皮肤炎症和相关综合征的化妆美容用和/或药用组合物
BR112021004542A2 (pt) inibidores do inibidor de ativador de plasminogênio 1 (pai-1) e usos para os mesmos
US20250143905A1 (en) Topical treatment for anorectal disorders with and without seat cushion
JP2016510061A (ja) 皮膚傷痕の色整合化を改善するためのベータ−２−アドレナリン作動性受容体アゴニスト
JPH10139669A (ja) 脂漏性角化症治療剤
WO2020234439A1 (en) Composition and use thereof for the treatment of cutaneous mastocytosis
KR20190017801A (ko) 티몰롤을 포함하는 조성물 및 국소 투여에 의한 주사의 치료에 있어서의 이들의 용도
JPH0971539A (ja) 外用鎮痒剤
JP3538367B2 (ja) 皮膚組織障害治療・予防・改善用外用剤
WO2024121065A1 (en) Dyclonine for use in the topical treatment of hand-foot syndrome
CN116983415A (zh) 一种用于预防和治疗皮下毛细血管扩张、毛细血管炎症及相关继发症的组合物及其应用
Charles 34 Postinflammatory Hyperpigmentation
WO2019093359A1 (ja) 末梢毛細血管の血流量増加剤
JP2001163782A (ja) 皮膚疾患治療用外用剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241003

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241115